Trial Condition(s):

Metastatic castration-resistant prostate cancer (mCRPC)

Descriptive analysis of clinical outcomes in patients with prostate gland cancer, which spreads to other parts of the body, who were treated first with novel anti-hormone therapy followed by a second line treatment with novel anti-Hormone therapy or RadIum-223 (Xofigo). (PHENIX)

Bayer Identifier:

20526

ClinicalTrials.gov Identifier:

NCT03896984

EudraCT Number:

Not Available

Study Completed

Trial Purpose

In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy (NAH) or Radium-223 (Xofigo) after a prior NAH therapy (first line treatment). Additionally the researchers are also interested in the occurrence of bone fractures and other skeletal events. Basis for this study will be the US based Flatiron database which provides access to clinical data for cancer patients.

Inclusion Criteria
- Patients with documented mCRPC receiving 1L NAHs.
- Initiation of  Ra-223 after 1L NAH therapy, or
- Initiation of sequential NAH therapy after 1L NAH therapy
Exclusion Criteria
- Patients involved in clinical trials
- Patients who received combined therapies in 1L or 2L

Trial Summary

Enrollment Goal
346
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

US Flatiron prostate cancer database

Whippany, United States, 07981

Status
Completed
 

Trial Design